Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, delivered four poster presentations at the 2010 International Conference on Alzheimer’s Disease (ICAD) in Honolulu, Hawaii. These presentations discussed NuroPro, Power3′s diagnostic test, and focused on Power3′s Alzheimer’s disease blood serum biomarkers, test and clinical validation trials.
“In preparation for commercialization, our objective at this meeting was to show how Power3′s protein biomarkers and blood tests provide superior solutions for diagnosis and drug response to improve the treatment of Alzheimer’s disease,” said Dr. Ira L. Goldknopf, Power3′s President and Chief Scientific Officer. “It was gratifying to receive substantial attention to our posters from representatives of major pharma and clinical research institutions from around the world. They expressed surprise and enthusiasm for our findings, especially those relating to the methods by which Power3′s protein biomarkers indicate how patients respond to treatment with the three major anti-dementia drugs.”
“We are pleased that our blood tests specifically diagnose Alzheimer’s in patients, both pre- and post-treatment,” said Helen R. Park, MS, Chief Executive Officer of Power3, “and that our scientific collaborators, Dr. Marwan Sabbagh, Medical and Scientific Director of the Banner Sun Health Medical Research Institute, and Dr. Lourdes R. Bosquez, President of the Woodlands Behavioral Institute, Inc., presented along with us at the meeting in Hawaii.”
EpiCept Corporation (Nasdaq:EPCT) reports that Jack Talley, President and CEO, will be presenting at the 9th Annual BIO Investor Forum on Tuesday, October 5, 2010 at 1:30 p.m. Pacific time at the Palace Hotel in San Francisco, California. Mr. Talley will present new interim data from the Company�s NCI-sponsored clinical trial of EpiCept NP-1 for the treatment of chemotherapy peripheral neuropathy in addition to providing a company overview.
The presentation will be available live via webcast on October 5, 2010 and for 90 days thereafter. The webcast can be accessed by visiting www.epicept.com.
EpiCept is focused on the development and commercialization of pharmaceutical products for the treatment of cancer and pain. The Company’s lead product is Ceplene, which has been granted full marketing authorization by the European Commission for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia (AML) in first remission. The Company has two oncology drug candidates currently in clinical development that were discovered using in-house technology and have been shown to act as vascular disruption agents in a variety of solid tumors. The Company’s pain portfolio includes EpiCept NP-1, a prescription topical analgesic cream in late-stage clinical development designed to provide effective long-term relief of pain associated with peripheral neuropathies.
EpicorSoftware Corporation (NASDAQ: EPIC), a leading provider of enterprise business software solutions for the midmarket and divisions of Global 1000 companies, reports that Solinoff Corporation, a modern office furniture manufacturer with more than 20 years of experience in the Colombian market, has selected Epicor’s next-generation enterprise resource planning (ERP) solution to increase efficiency and improve operations management.
After 10 years of relying on an in-house solution, Solinoff determined that expanding its current software solution would not support the company’s plans for growth. During the past few years, Solinoff has grown exponentially and its operation levels no longer allowed proper control for the management and administration areas of the business. After a comprehensive assessment of ERP providers, Solinoff began an in-depth evaluation period where they studied three ERP providers and concluded that Epicor was clearly the best solution to meet the company’s needs. Solinoff was looking for a solution that would easily adapt to its manufacturing process; the Epicor solution matched the company’s requirements.
Epicor Software is a global leader delivering business software solutions to the manufacturing, distribution, retail, hospitality and services industries. With 20,000 customers in over 150 countries, Epicor provides integrated enterprise resource planning (ERP), customer relationship management (CRM), supply chain management (SCM) and enterprise retail software solutions that enable companies to drive increased efficiency and improve profitability. Founded in 1984, Epicor takes pride in more than 25 years of technology innovation delivering business solutions that provide the scalability and flexibility businesses need to build competitive advantage. Epicor provides a comprehensive range of services with a single point of accountability that promotes rapid return on investment and low total cost of ownership, whether operating business on a local, regional or global scale.
Epiq Systems, Inc. (Nasdaq:EPIQ), a leading provider of technology solutions for the legal profession, announced that its Board of Directors has approved a cash dividend of 3.5 cents per common share. The quarterly dividend will be payable November 18, 2010, to shareowners of record at the close of business on October 28, 2010.
Epiq Systems is a leading global provider of integrated technology solutions for the legal profession. Our solutions streamline the administration of bankruptcy, litigation, financial transactions and regulatory compliance matters. We offer innovative technology solutions for electronic discovery, document review, legal notification, claims administration and controlled disbursement of funds. Our clients include leading law firms, corporate legal departments, bankruptcy trustees, government agencies and other professional advisors who require innovative technology, responsive service and deep subject-matter expertise.
No comments:
Post a Comment